In the last years, the increase in antimicrobial resistance, together with a lack of new drugs for the treatment of bacterial infections resistant to classical antibiotics are of growing concern. Moreover, some of current therapies induce severe side effects and are often difficult to administer. In 2012 the FDA approved the use of bedaquiline, as the first new very effective drug against TB in the last 40 years. Despite its effectiveness, unfortunately bedaquiline side effects can be so dangerous that at present it is to be prescribed only when no other treatment options are available. The development of effective and safe nanotechnology-based methods can be particularly relevant to increase antimicrobial concentration at the site of infec...
Background: In 2014, an estimated 1.8 million people died from Mycobacterium tuberculosis (MTB); mor...
357-366The era of nanotechnology has allowed new research strategies to flourish in the field of dr...
Tuberculosis (TB) is currently the second deadliest infectious disease. Existing antitubercular ther...
International audienceIn the last years, the increase in antimicrobial resistance, together with a l...
Resumen del trabajo presentado a la VIII National Conference BIFI, celebrada en el Edificio I+D Camp...
Resumen del trabajo presentado al 7th Congress of European Microbiologists, celebrado en Valencia (E...
Tuberculosis (TB), one of the oldest recorded diseases of mankind, remains a major health threat to ...
The appearance and rapid spread of drug resistant strains of tuberculosis (TB), one of the deadliest...
The combination drug regimens that have long been used to treat tuberculosis (TB), caused by Mycobac...
The antimicrobial drugs currently used for the management of tuberculosis (TB) exhibit poor bioavail...
Resumen del trabajo presentado al IMI Translocation - Novel approaches to fight bacteria: "From unde...
Tuberculosis (TB) is a contagious infection that usually attacks not only the lungs, but also brain ...
International audienceTuberculosis (TB) is a contagious infection that usually attacks not only the ...
Tuberculosis (TB) is an old disease that may have coexisted with humans for at least 15,000 years b...
Background: In 2014, an estimated 1.8 million people died from Mycobacterium tuberculosis (MTB); mor...
Background: In 2014, an estimated 1.8 million people died from Mycobacterium tuberculosis (MTB); mor...
357-366The era of nanotechnology has allowed new research strategies to flourish in the field of dr...
Tuberculosis (TB) is currently the second deadliest infectious disease. Existing antitubercular ther...
International audienceIn the last years, the increase in antimicrobial resistance, together with a l...
Resumen del trabajo presentado a la VIII National Conference BIFI, celebrada en el Edificio I+D Camp...
Resumen del trabajo presentado al 7th Congress of European Microbiologists, celebrado en Valencia (E...
Tuberculosis (TB), one of the oldest recorded diseases of mankind, remains a major health threat to ...
The appearance and rapid spread of drug resistant strains of tuberculosis (TB), one of the deadliest...
The combination drug regimens that have long been used to treat tuberculosis (TB), caused by Mycobac...
The antimicrobial drugs currently used for the management of tuberculosis (TB) exhibit poor bioavail...
Resumen del trabajo presentado al IMI Translocation - Novel approaches to fight bacteria: "From unde...
Tuberculosis (TB) is a contagious infection that usually attacks not only the lungs, but also brain ...
International audienceTuberculosis (TB) is a contagious infection that usually attacks not only the ...
Tuberculosis (TB) is an old disease that may have coexisted with humans for at least 15,000 years b...
Background: In 2014, an estimated 1.8 million people died from Mycobacterium tuberculosis (MTB); mor...
Background: In 2014, an estimated 1.8 million people died from Mycobacterium tuberculosis (MTB); mor...
357-366The era of nanotechnology has allowed new research strategies to flourish in the field of dr...
Tuberculosis (TB) is currently the second deadliest infectious disease. Existing antitubercular ther...